Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-25 @ 9:33 PM
Study NCT ID:
NCT05278351
Status:
UNKNOWN
Last Update Posted:
2023-03-31
First Post:
2022-03-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-13
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-08
First Submit QC Date:
None
Study First Post Date:
2022-03-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-28
Last Update Post Date:
2023-03-31
Last Update Post Date Type:
ACTUAL